Context Therapeutics reports Q2 results

1 hour ago 1

Context Therapeutics press release (NASDAQ:CNTX): Q2 net loss of $8.8 million, as compared to a loss of $2.3 million for the second quarter of 2024.
Cash and cash equivalents were $83.5 million at June 30, 2025, compared to $94.4 million at December 31, 2024.
The company expects its cash and cash equivalents will be sufficient to fund its operations into 2027.

Recommended For You